Quantcast
Home > Quotes > KIN

Kindred Biosciences, Inc. Common Stock (KIN) Quote & Summary Data

KIN 
$13.45
*  
0.10
0.75%
Get KIN Alerts
*Delayed - data as of Sep. 18, 2018  -  Find a broker to begin trading KIN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
18
Today's High / Low
$ 13.95 / $ 13.30
Share Volume
105,095
50 Day Avg. Daily Volume
202,692
Previous Close
$ 13.35
52 Week High / Low
$ 15.75 / $ 6.80
Market Cap
454,606,503
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.3

Intraday Chart

Shares Traded

Share Volume:
105,095
50 Day Avg. Daily Volume:
202,692

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.39

Trading Range

The current last sale of $13.45 is 97.79% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.95 $ 15.75
 Low: $ 13.30 $ 6.80

ETFs with KIN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
0.93% iShares Inc iShares MSCI Belgium ETF (EWK) -1.47 (-6.97%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a pre-commercialization biopharmaceutical company focused on saving and improving the lives of pets. Our mission is to bring to our pets the same kinds of safe and effective medicines that our human family members enjoy. Our core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats and horses. We believe this approach will lead to shorter development times and higher approval rates than pursuing new, non-validated compounds and targets. Our current portfolio includes over 20 product candidates in development consisting of both small molecule pharmaceuticals and biologics. We were incorporated in Delaware in September 2012. The address of our principal executive offices is 1555 Bayshore Highway, Suite 200, Burlingame, CA 94010.  ... More ...  


Risk Grade

Where does KIN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.30
Open Date:
Sep. 18, 2018
Close Price:
$ 13.45
Close Date:
Sep. 18, 2018

Consensus Recommendation

Analyst Info